Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Virtuell hembaserad träningsinsats (Rise) för att förbättra cancerrelaterad kognitiv nedsättning och tarmmikrobiom hos ungdomar och unga vuxna hjärntumöröverlevande

4 november 2026 uppdaterad av: Jinbing Bai, Emory University

Praktiskt taget levererade hembaserad träningsinsats om kognitiv försämring och tarmmikrobiom hos ungdomar och unga vuxna tumöröverlevande: En pilot randomiserad kontrollerad studie

This clinical trial evaluates the impact of a research intervention of virtually supervised exercise program (RISE) on cancer-related cognitive impairment (CRCI), physical activity in adolescent and young adult (AYA) brain tumor survivors. This clinical trial also evaluates the impact of RISE on the collection of microorganisms that exist in the intestines (gut microbiome). Up to 45% of AYA brain tumor survivors experience CRCI, including issues with attention and memory. CRCI can have a negative impact on education, independent living and can worsen long-term quality of life. Moderate-intensity levels of exercise, particularly aerobic and resistance training, have been shown to improve cognitive function. Additionally, exercise can change the composition and function of the gut microbiome, which may lead to improved cognitive function. Unfortunately, only about 50% of AYAs with cancer receive exercise information or meet the physical activity recommendations. Tailoring a virtually delivered exercise intervention to meet the unique needs of AYAs may improve access to exercise. Participating in the virtual home-based exercise intervention, RISE, may improve physical activity and cognitive impairment in AYA brain tumor survivors and may also help researchers understand the relationship of exercise on the gut microbiome and cognitive function.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVES:

I. Evaluate the feasibility of conducting a two-site pilot randomized controlled trial (RCT) to test the RISE in AYA brain tumor survivors.

II. Examine the impact of RISE on CRCI (primary) and physical activity (secondary).

EXPLORATORY OBJECTIVE:

I. Explore the impact of RISE on the gut microbiome diversity and composition.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (RISE INTERVENTION): Patients receive access to Physitrack and participate in personalized, progressive aerobic training over 30-40 minutes 3-5 days a week and strength training exercises 2 days a week for 12 weeks. Patients also receive active lifestyle behavior coaching over 10 minutes on 2 days a week for weeks 1-4 and then once weekly for weeks 5-12.

ARM II (ATTENTION CONTROL): Patients receive calls from the trainer once weekly for 12 weeks. Patients also wear a Fitbit for 7 days at baseline to week 12.

After completion of study intervention, patients are followed up at week 18.

Studietyp

Interventionell

Inskrivning (Beräknad)

60

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
    • Texas
      • Houston, Texas, Förenta staterna, 77030

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

15 år till 39 år (Barn, Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 15-39 years
  • With primary brain tumor with cranial radiotherapy
  • 6 months to 4 years post cranial radiotherapy
  • Functional Assessment of Cancer Therapy (FACT)-Cognitive Function score < 60 based on self-report (used among AYAs with non-neural cancer)
  • Able to provide informed consent/assent
  • Able to walk and receive clearance from a provider to participate based on the Physical Activity Readiness Questionnaire
  • Currently engaging in < 150 minutes of physical activity per week
  • Willing to use smartphone-based applications (app)

Exclusion Criteria:

  • Secondary malignancies, germline genetic syndrome, or recurrent disease requiring re-irradiation of the brain
  • Moderate to severe traumatic brain injury with brain damage beyond that expected from brain tumor and treatment
  • Developmental disorders (e.g., autism) or major psychotic illness (e.g., schizophrenia, depression) to avoid confounding impact related to these disorders

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm I (RISE)

Patients receive access to Physitrack and participate in personalized, progressive aerobic training over 30-40 minutes 3-5 days a week and strength training exercises 2 days a week for 12 weeks. Patients also receive active lifestyle behavior coaching over 10 minutes on 2 days a week for weeks 1-4 and then once weekly for weeks 5-12.

Ancillary studies

Participate in personalized, progressive aerobic training

Andra namn:
  • Aerob aktivitet

Receive active lifestyle behavior coaching

Andra namn:
  • Beteendekonditionerande terapi
  • Beteendeändring
  • Ändringar av beteende eller livsstil
  • Beteendeterapi
  • Beteendeinterventioner
  • Beteendebehandling
  • Beteendebehandlingar

Receive access to Physitrack

Participating in strength training exercises

Andra namn:
  • Styrketräning
Aktiv komparator: Arm II (attention control)

Patients receive calls from the trainer once weekly for 12 weeks. Patients also wear a Fitbit for 7 days at baseline to week 12.

Ancillary studies

Receive calls from the trainer

Andra namn:
  • Aktiv uppföljning
  • Uppföljning av kliniska tecken
  • CLSFUP
  • Uppföljning
  • uppföljning
  • Följt

Wear a Fitbit monitor

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Enrollment
Tidsram: Up to 1.5 years

Feasibility will be ≥ 50% enrollment of eligible survivors. Descriptive statistics (e.g., frequency and percentage) will be used.

Up to 1.5 years
Adherence to research intervention of virtually supervised exercise program (RISE)
Tidsram: Up to 12 weeks

Feasibility will be ≥ 75% adherence to RISE. Descriptive statistics (e.g., frequency and percentage) will be used.

Up to 12 weeks
Retention
Tidsram: Up to 12 weeks

Feasibility will be ≥ 80% retention at end of intervention. Descriptive statistics (e.g., frequency and percentage) will be used.

Up to 12 weeks
Acceptability
Tidsram: Up to 18 weeks

Will use an 11-item acceptability questionnaire. A ≥ 4 ("agree" to "strongly agree") per item equates to acceptability. Descriptive statistics (e.g., frequency and percentage) will be used.

Up to 18 weeks
Change in physical activity levels
Tidsram: Baseline up to 18 weeks

Will be measured by Fitbit. Physical activity estimates considered as valid if the monitor is worn ≥ 10 hours/day on ≥ 4 days. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

Baseline up to 18 weeks
Change in cancer-related cognitive impairment
Tidsram: Baseline up to 18 weeks

Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

Baseline up to 18 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Gut microbiome
Tidsram: Up to 18 weeks

Fecal specimens will be collected for the gut microbiome. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

Up to 18 weeks
Physical function
Tidsram: At baseline and at 12 and 18 weeks

Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

At baseline and at 12 and 18 weeks
Patient Quality of Life
Tidsram: At baseline and at 12 and 18 weeks

Will be assessed by Patient Reported Outcomes Measurement Information System-29 recommended. Will use mixed-effect analysis of variance to model the correlation with timepoint and treatment group plus interaction if applicable, clustering on patient to control for repeated measures, and controlling for baseline measure and other covariates, which are considered prognostic or differ at baseline. A 95% level of statistical confidence will be assumed in all statistical testing.

At baseline and at 12 and 18 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Jinbing Bai, PhD, RN, Emory University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

13 februari 2025

Primärt slutförande (Beräknad)

31 juli 2027

Avslutad studie (Beräknad)

31 juli 2028

Studieregistreringsdatum

Först inskickad

23 januari 2025

Först inskickad som uppfyllde QC-kriterierna

23 januari 2025

Första postat (Faktisk)

29 januari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

4 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera